Abstract:Hepatocellular carcinoma (HCC) is one of the most prevalent life-threatening human cancers and the leading cause of cancer-related mortality, with increased global incidence within the last decade. Identification of effective diagnostic and prognostic biomarkers would enable reliable risk stratification and efficient screening of high-risk patients, thereby facilitating clinical decision-making. Herein, we performed a comprehensive, robust DNA methylation analysis based on genome-wide DNA methylation profiling. We constructed a diagnostic signature with five DNA methylation markers, which precisely distinguished HCC patients from normal controls. Cox regression and LASSO analysis were applied to construct a prognostic signature with four DNA methylation markers. A one-to-one correlation analysis was carried out between genes of the whole genome and our prognostic signature. Exploration of the biological function and the role of the underlying significantly correlated genes was conducted. A mixed dataset of 463 HCC patients and 253 normal controls, derived from six independent datasets, was used to valid the diagnostic signature. Results showed a specificity of 96.84% and sensitivity of 96.77%. Class scores for the diagnostic signature were significantly different between normal controls, individuals with liver diseases, and HCC patients. The present signature has the potential to serve as a biomarker to monitor health in normal controls. Additionally, HCC patients were successfully separated into low-risk and high-risk groups by the prognostic signature, with a better prognosis for patients in the low-risk group. Kaplan-Meier and ROC analysis confirmed that the prognostic signature performed well. We found eight of the top ten genes to positively correlate with risk scores of the prognostic signature, and to be involved in cell cycle regulation. This eight-gene panel also served as a prognostic signature. The robust evidence presented in this study therefore demonstrates the effectiveness of the prognostic signature. In summary, we constructed diagnostic and prognostic signatures, which have potential for use in diagnosis, surveillance, and prognostic prediction for HCC patients. Eight genes that were significantly and positively correlated with the prognostic signature were strongly associated with cell cycle processes. Therefore, the prognostic signature can be used as a guide by which to measure responsiveness to cell-cycle-targeting agents.

Hydroxymethylation and Epigenetic Drugs: New Insights into the Diagnosis and Treatment in Epigenetics of Hepatocellular Carcinoma

Emerging Biomolecules for Practical Theranostics of Liver Hepatocellular Carcinoma.

Construction and Validation of Novel Diagnostic and Prognostic DNA Methylation Signatures for Hepatocellular Carcinoma

Deoxyribonucleic Acid 5-Hydroxymethylation in Cell-Free Deoxyribonucleic Acid, a Novel Cancer Biomarker in the Era of Precision Medicine

A novel strategy for the diagnosis, prognosis, treatment, and chemoresistance of hepatocellular carcinoma: DNA methylation.

Research Progress on the Role of Epigenetic Methylation Modification in Hepatocellular Carcinoma

Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: From basic research to clinical application

Whole-genome DNA methylation and hydroxymethylation profiling for HBV-related hepatocellular carcinoma

Emerging Role of Molecular Diagnosis and Personalized Therapy for Hepatocellular Carcinoma

Epigenetics of Hepatocellular Carcinoma: a New Horizon.

Molecular Diagnosis and Therapy of Hepatocellular Carcinoma: Achievements and Challenges

Role of ten-eleven translocation proteins and 5-hydroxymethylcytosine in hepatocellular carcinoma

Non-coding RNA Methylation Modifications in Hepatocellular Carcinoma: Interactions and Potential Implications

Early Diagnosis and Therapeutic Strategies for Hepatocellular Carcinoma: from Bench to Bedside

The Association Between Methylation Patterns of DNAH17 and Clinicopathological Factors in Hepatocellular Carcinoma

Hydroxymethylation and tumors: can 5-hydroxymethylation be used as a marker for tumor diagnosis and treatment?

Unmasking the pathological and therapeutic potential of histone deacetylases for liver cancer

DNA Methylation and Hepatocellular Carcinoma

Epigenetic Modification-Related Mechanisms of Hepatocellular Carcinoma Resistance to Immune Checkpoint Inhibition

Long Noncoding RNA, the Methylation of Genomic Elements and Their Emerging Crosstalk in Hepatocellular Carcinoma.

Novel Molecular Targets for Diagnosis and Treatment of Hepatocellular Carcinoma.